MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

34.26 +0.96 (+2.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
News headline image
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗
It's not much of a rivalry yet. 
Via The Motley Fool
News headline image
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished ↗
In a slow news month for the company, investors focused on the cost of its phase 3 trials rather than their benefits. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
There are other reasons to pay attention to Viking Therapeutics. 
Via The Motley Fool
Viking Therapeutics (NASDAQ:VKTX) Q2 Loss Beats Estimates, Shares Edge Lower as Obesity Pipeline Progresses ↗
Via Chartmill
News headline image
Viking Therapeutics Stock Moves Lower: What's Going On? ↗
Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know. 
Via Benzinga
News headline image
Viking Therapeutics Q2 Earnings Call Highlights ↗
Viking Therapeutics (NASDAQ:VKTX) reported a wider second-quarter loss as the company increased spending to advance its obesity pipeline, including its lead dual GLP-1/GIP receptor agonist, VK2735,... 
Via MarketBeat
Topics Earnings
News headline image
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case ↗
The stock looks like a high-risk, high-reward play. 
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
Viking's latest program seeks to push the envelope in weight loss efficacy. 
Via The Motley Fool
News headline image
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." ↗
Wall Street analysts are highly bullish on Viking Therapeutics, not least because of its promising weight-loss drug, with ongoing and upcoming phase 3 trials. 
Via The Motley Fool
News headline image
This GLP-1 Stock Could Double by 2030. Here's Why ↗
Investors need to ask tough questions before initiating a position in this biotech company. 
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
There are good reasons to invest in Lilly and to hold off. 
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years ↗
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an annualized basis producing an average annual return of 40.15%. Currently, Viking Therapeutics has a... 
Via Benzinga
News headline image
Is This Biotech Stock a Buy After Its Massive Rally? ↗
This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the payoff arrives. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Eli Lilly? ↗
The stock has soared 400% in recent years. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare. 
Via The Motley Fool
News headline image
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗
The weight-loss market is crowded, but this company's lead drug candidate has several key advantages. 
Via The Motley Fool
News headline image
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗
This biotech might have a bright future, but it'll need to survive against the incumbents to do so. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗
The stock is known to soar on good news. 
Via The Motley Fool
News headline image
Here's Why Viking Therapeutics Stock Surged Higher in June ↗
Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Going to $100? ↗
That would be an impressive run if it could get there soon. 
Via The Motley Fool
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare. 
Via The Motley Fool
News headline image
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy? ↗
The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock a No-Brainer Buy Below $35? ↗
The drugmaker is looking to challenge the leaders in the weight loss market. 
Via The Motley Fool
News headline image
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk ↗
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed. 
Via The Motley Fool
News headline image
Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 Years ↗
Shoppers keep coming back to these companies. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Viking Therapeutics Stock Going to $100? ↗
Viking stock is known for soaring after positive news. 
Via The Motley Fool
News headline image
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% ↗
If you look beyond the upside potential, there's still plenty of risk to navigate past. 
Via The Motley Fool
News headline image
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't ↗
This particular sector may suit cautious and aggressive investors. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story